Want to see BRTX full AI Analyst Report?
Top Page
BioRestorative Therapies
(NASDAQ:BRTX)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.22
▼(-25.86% Downside)
Action:Reiterated
Date:07/31/26
The score is driven primarily by weak financial performance (tiny, declining revenue; extreme losses; significant cash burn) and bearish technicals (price well below 20/50/100/200-day averages). Valuation provides limited support because earnings are negative and no dividend yield is available. Corporate events add incremental risk due to governance disruption and heightened dilution concerns.
Positive Factors
Very low leverage / effectively no debt
Effectively zero reported debt reduces interest burden and lowers near-term solvency risk, giving management more flexibility to prioritize R&D or financing terms. Over 2–6 months this structural low-leverage profile improves optionality when raising capital or negotiating lender covenants.
Negative Factors
Persistent, heavy cash burn
Sustained negative operating and free cash flow of roughly -$12M TTM creates structural funding pressure relative to the company's tiny revenue base. Over months this requires recurring external financing, raising dilution risk and potentially constraining R&D timelines or commercialization efforts if capital is scarce or costly.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage / effectively no debt
Effectively zero reported debt reduces interest burden and lowers near-term solvency risk, giving management more flexibility to prioritize R&D or financing terms. Over 2–6 months this structural low-leverage profile improves optionality when raising capital or negotiating lender covenants.
Read all positive factors
BioRestorative Therapies (BRTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.22M
Dividend YieldN/A
Average Volume (3M)417.77K
Price to Earnings (P/E)―
Beta (1Y)1.26
Revenue Growth-8.47%
EPS Growth25.61%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.23
Shares Outstanding25,478,170
10 Day Avg. Volume225,011
30 Day Avg. Volume417,769
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)29.75
Price to Sales (P/S)29.50
P/FCF Ratio-0.97
Enterprise Value/Market Cap0.10
Enterprise Value/Revenue1.44
Enterprise Value/Gross Profit1.56
Enterprise Value/Ebitda-0.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.33
Revenue Forecast (FY)$2.50M
BioRestorative Therapies Business Overview & Revenue Model
Company Description
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic ...
How the Company Makes Money
null...
BioRestorative Therapies Earnings Call Summary
Earnings Call Date:Nov 12, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Aug 18, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant milestones in the company's clinical and commercial development, such as the Fast Track designation for BRTX-100 and a new patent for ThermoStem. However, these were counterbalanced by a sharp revenue decline and increased net loss compared to the previous year. Despite the financial setbacks, the overall sentiment is cautiously optimistic with strategic developments and a strengthened financial position.Positive Updates
Fast Track Designation for BRTX-100
The BRTX-100 program for chronic lumbar disc disease was granted Fast Track designation by the FDA, a major milestone that enables closer collaboration with the FDA for potential accelerated Biologic License Application (BLA) approval.
Negative Updates
Significant Revenue Decline
Third-quarter 2025 revenues were $11,800, a significant decrease from $233,600 in Q3 2024, primarily due to the timing of orders for the developing biocosmeceutical revenue stream.
Read all updates
Q3-2025 Updates
Positive
Negative
Fast Track Designation for BRTX-100
The BRTX-100 program for chronic lumbar disc disease was granted Fast Track designation by the FDA, a major milestone that enables closer collaboration with the FDA for potential accelerated Biologic License Application (BLA) approval.
Read all positive updates
Company Guidance
In the third quarter of 2025, BioRestorative Therapies reported a mixed financial performance, with revenues significantly declining to approximately $11,800 from $233,600 in the same period of 2024, primarily due to timing in the biocosmeceutical revenue stream. The company reported a loss from operations of $3.7 million, up from $2.3 million in the previous year, and a net loss of $3 million or $0.33 per share, compared to a net loss of $1 million or $0.13 per share in 2024. Despite these financial challenges, BioRestorative Therapies ended the quarter with $4.5 million in cash, cash equivalents, and marketable securities, excluding $1.1 million from recent financing. On the clinical front, the company is advancing its Phase II BRTX-100 study for chronic lumbar disc disease, with enrollment nearing completion and a potential Type B FDA meeting anticipated. The company also highlighted substantial progress in its ThermoStem program targeting obesity, while continuing discussions for a potential licensing agreement. The biocosmeceuticals business shows promise, with strategic leadership changes and a focus on expanding distribution channels, although revenue guidance remains uncertain.BioRestorative Therapies Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 357.87K | 359.70K | 401.00K | 145.80K | 119.80K | 46.00K |
| Gross Profit | 329.55K | 335.86K | 372.93K | 145.80K | 119.80K | 46.00K |
| EBITDA | -10.85M | -14.03M | -8.79M | -14.97M | -13.10M | -42.40M |
| Net Income | -11.06M | -14.24M | -8.98M | -10.42M | -13.22M | -44.30M |
Balance Sheet | ||||||
| Total Assets | 4.64M | 4.08M | 12.28M | 12.61M | 16.43M | 22.45M |
| Cash, Cash Equivalents and Short-Term Investments | 3.59M | 2.95M | 10.73M | 11.07M | 14.75M | 21.03M |
| Total Debt | 34.52K | 0.00 | 0.00 | 162.32K | 301.64K | 670.70K |
| Total Liabilities | 1.61M | 3.72M | 3.75M | 2.61M | 6.14M | 856.50K |
| Stockholders Equity | 3.03M | 356.74K | 8.53M | 10.00M | 10.29M | 21.60M |
Cash Flow | ||||||
| Free Cash Flow | -11.90M | -10.91M | -8.34M | -6.60M | -6.35M | -3.36M |
| Operating Cash Flow | -11.82M | -10.79M | -8.23M | -6.43M | -5.91M | -3.33M |
| Investing Cash Flow | 7.50M | 8.90M | 514.53K | 3.25M | -13.40M | -30.66K |
| Financing Cash Flow | 6.20M | 2.85M | 7.38M | 2.35M | 0.00 | 21.32M |
BioRestorative Therapies Technical Analysis
Negative
0.29
Price Trends
0.35
Negative
0.30
Negative
0.67
Negative
Market Momentum
-0.04
Positive
21.93
Positive
2.13
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BRTX, the sentiment is Negative. The current price of 0.29 is below the 20-day moving average (MA) of 0.30, below the 50-day MA of 0.35, and below the 200-day MA of 0.67, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 21.93 is Positive, neither overbought nor oversold. The STOCH value of 2.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BRTX.
BioRestorative Therapies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $20.54M | -0.35 | -264.79% | ― | ― | 58.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $11.31M | -1.11 | -150.61% | ― | ― | 53.06% | |
43 Neutral | $12.94M | -0.06 | 223.66% | ― | ― | -101.45% | |
41 Neutral | $5.22M | -0.17 | -423.84% | ― | -8.47% | 25.61% | |
41 Neutral | $18.84M | -1.69 | -73.29% | ― | -43.86% | 49.21% |
* Healthcare Sector Average
BRTX
BioRestorative Therapies
0.21
-1.28
-85.91%
CLRB
Cellectar Biosciences
2.56
-2.31
-47.43%
MRKR
Marker Therapeutics
1.23
-0.02
-1.60%
COCP
Cocrystal Pharma
0.98
-0.67
-40.61%
AEON
AEON Biopharma
0.30
-0.43
-59.45%
BioRestorative Therapies Corporate Events
Business Operations and StrategyExecutive/Board ChangesLegal ProceedingsRegulatory Filings and Compliance
BioRestorative Therapies Overhauls Leadership and Board Governance
Negative
Jul 17, 2026
On July 8, 2026, BioRestorative Therapies amended executive employment agreements for its then chief executive, chief financial officer and vice president of research and development, narrowing severance and equity-vesting benefits to apply only i...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
BioRestorative Revamps Board Following New Loan Agreement
Neutral
Jun 12, 2026
On June 10, 2026, BioRestorative Therapies entered into a revolving loan agreement with Bowery Group LLC, giving the company the ability to draw up to $1 million for general corporate purposes under a 12% annual interest rate, with a one-year matu...
Business Operations and StrategyExecutive/Board Changes
BioRestorative Therapies Finalizes Executive Agreement with R&D VP
Positive
Jun 12, 2026
On June 10, 2026, BioRestorative Therapies entered into a new executive employment agreement with Francisco Silva, its Vice President of Research and Development, setting a term through June 10, 2029 and formalizing his role, duties and primary wo...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
BioRestorative Therapies Extends Executive Leadership Employment Agreements
Positive
May 29, 2026
On May 27, 2026, BioRestorative Therapies, Inc. signed new employment agreements with President, Chief Executive Officer and Chairman Lance Alstodt and Chief Financial Officer Robert Kristal, extending their terms through May 27, 2029 while keepin...
Executive/Board Changes
BioRestorative Therapies Boosts Executive Compensation and Equity Incentives
Positive
May 1, 2026
On May 1, 2026, BioRestorative Therapies, Inc.’s compensation committee approved discretionary cash bonuses for its named executive officers for services rendered in 2025, reflecting increases over the prior year in both salary and equity-ba...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.